Author:
de Vlieger Jon S. B.,Crommelin Daan J. A.,Tyner Katherine,Drummond Daryl C.,Jiang Wenlei,McNeil Scott E.,Neervannan Sesha,Crist Rachael M.,Shah Vinod P.
Publisher
Springer Science and Business Media LLC
Reference25 articles.
1. USA FDA draft guidance “Drug Products, Including Biological Products that Contain Nanomaterials.” December 2017.
https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM588857.pdf
.
2. USA FDA draft guidance “Assay development and validation for immunogenicity testing of therapeutic protein products.” April 2016
https://www.fda.gov/downloads/Drugs/Guidances/UCM192750.pdf
.
3. USA FDA guidance for industry considering whether an FDA-regulated product involves the application of nanotechnology’. June 2014.
https://www.fda.gov/downloads/regulatoryinformation/guidances/ucm401695.pdf
.
4. D’Mello SR, Cruz CN, Chen ML, Kapoor M, Lee SL, Tyner KM. The evolving landscape of drug products containing nanomaterials in the United States. Nat Nanotechnol. 2017;12:523–52.
5. Ambardekar VV, Stern ST. NBCD pharmacokinetics and bioanalytical methods to measure drug release. In: Crommelin DJA, De Vlieger JSB, editors. Non-biological complex drugs: the science and the regulatory landscape. Switzerland: Springer International Publishing; 2015. p. 261–87.
Cited by
20 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献